nrdr.acr.org

### \* Required field



nrdr.acr.org

COVID Testing Status	O Tested: Positive O Tested: Negative O Tested: Inconclusive O Unknown O Testing Not Performed
COVID Vaccine	O No O Yes O Unknown
COVID Vaccine Date	/(mm/dd/yyyy)
COVID Vaccine Manufacturer	O       Johnson & Johnson Janssen       O       Novavax       O       Oxford - AstraZeneca         O       Moderna       O       Pfizer - BioNTech       O       Unknown         O       Moderna       O       Other, please specify:
COVID Vaccination Site	O     Right Arm     O     Other       O     Left Arm     O     Unknown
Date of Death:	Date of Death:
4. *Examination Date:	/(mm/dd/yyyy)
Rescheduled Examination?	O Yes O No O Unknown
Originally scheduled Examination date	/(mm/dd/yyyy)
Rescheduled reason:	O Patient (COVID/2019 Coronavirus related)     O Patient (Other)     O Unknown       O Facility (COVID/2019 Coronavirus related)     O Facility (Other)     O Unknown

v 1.27

### **Exam Form**

nrdr.acr.org

v 1.27

5A. General								
Appropriateness of Screening								
5A1. *Smoking Status	Select one:       O         O       Current smoker       O         O       Smoker, current status unknown       O							
	Number of pack-years of smoking:							
	Number of years since quit:							
5A2. Did physician provide smoking cessation guidance to patient?	O No O Yes	O Unknown						
5A3. Is there documentation of shared decision making?	O No O Yes	O Unknown						
5A4. *Patient's Height		(inches)						
5A5. *Patient's Weight		(pounds)						
5A6. Other comorbidities listed on patient record that limit life expectancy:	Select all that apply:         COPD       Pulmonary fibrosis         Congestive heart failure       Peripheral vascular disease         Other, please specify:	<ul> <li>Emphysema</li> <li>Coronary artery disease</li> <li>Lung cancer</li> <li>Cancer other than lung cancer</li> </ul>						
Study Data								
5A7. *Radiologist (reading):	First Name:	Last Name:						
	First Name:	Last Name:						
5A8. Ordering Practitioner:	NPI:	) Unknown						
5A9. *Indication for Exam	Are there any signs or symptoms of lung cancer: If no, select one: O Baseline screen (prevalence screen, aka first screen) O Non-screening Chest CT assigned a Lung- RADS score and used in lieu of an annual screen to avoid repeat scanning.	O Yes O No O Annual screen (incidence screen, aka subsequent screens)						
5A10. *Modality:	O Low dose chest CT	O Routine chest CT						
	Scanner Name:	Manufacturer:						
5A11. *CT Scanner:	Model:							
	*CTDivol: (mGy)	*DLP: (mGy*cm)						
	Tube current-time: (mAs)	Tube voltage: (kV)						
5A12. Screening CT Radiation Exposure	Scanning time: (s)	Scanning volume: (cm)						
	Pitch:							
	*Reconstructed image width (nominal width of reconstructed image along z-axis) :	(mm)						

\* Required field

nrdr.acr.org

Select one: 0: Recalls (incomplete screen)  $\mathbf{O}$ Reasons for recall, select one: 0 I: Incomplete coverage 0 N: Noise O M: Respiratory motion O E: Expiration 0 OBa: Obscured by acute abnormality 0 UC: Unable to complete, please specify reason: U: Unknown 0 IP: Inflammatory or infectious 5A13. \*CT Screening Exam Result by process Lung-RADS Category: 0 1. Normal, continue annual screening 0 2. Benign appearance or behavior, continue annual screening 0 3. 6 month CT recommended 0 4A. 3 month CT recommended; may consider PET/CT 0 4B. Additional diagnostics and/or tissue sampling recommended 0 4X. Additional diagnostics and/or tissue sampling recommended - increased suspicion of malignancy. Ο Lung-RADS version used to report results O 1.0 0 1.1 0 Lung-RADS 2022 0 Other/Unknown O Yes O No If yes, what were the other findings? (Select all that apply.) □ Aortic aneurysm Coronary arterial Pulmonary fibrosis calcification, moderate or severe Mass, please specify, e.g., neck, mediastinum, liver, kidneys: \_\_\_\_ □ Other interstitial lung disease, select type if known: 5A14. \*Other clinically significant or UIP/IPF 0 potentially significant abnormalities -0 ILD, other, please specify: \_\_\_\_ CT exam result modifier S: 0 ILD, unknown □ Emphysema, moderate or severe Π Other clinically significant abnormalities, please specify: Unknown □ No clinically significant or potentially significant abnormalities 5A15. Prior history of lung cancer - CT O No O Yes O Unknown exam result modifier C: 5A16. Years since prior diagnosis of (years) lung cancer:

#### 5B. Follow-up within 1 year

Note: The following fields need to be collected for any follow-up imaging, biopsy, or surgical procedure for a patient who is in the screening program. There can be multiple follow-up records for each patient during the same year. Please complete a follow-up record for each procedure, even if the procedures occur on the same day. If a patient has a percutaneous biopsy and a bronchoscopy, for example, there should be a separate record for each of these.

#### \* Required field

American College of Radiology

nrdr.acr.org

v 1.27

5B1. *Date of follow-up	//(mm/dd/yyyy)								
	Select one:								
	O Low dose chest CT $O$ Routine chest CT $O$	PET/CT							
	O Bronchoscopy O Non-surgical biopsy O	Surgical resection							
5B2. *Follow-up diagnostic	O Other, please specify:	-							
	Select one:								
5B3. CT Diagnostic Exam Result by Lung-RADS Category:	<ul> <li>O 0: Recalls (incomplete screen) Reasons for recall, select one:         <ul> <li>I: Incomplete coverage</li> <li>N: Noise</li> <li>M: Respiratory motion</li> <li>E: Expiration</li> <li>Oba: Obscured by acute abnormality</li> <li>UC: Unable to complete, please specify reason:</li> <li>U: Unknown</li> <li>IP: Inflammatory or infectious process</li> </ul> </li> <li>1. Normal, continue annual screening</li> <li>2. Benign appearance or behavior, continue annual screening</li> <li>3. 6-month CT recommended</li> <li>4A. 3-month CT recommended; may consider PET/CT</li> <li>4B. Additional diagnostics and/or tissue sampling recommended</li> <li>4X. Additional diagnostics and/or tissue sampling recommended</li> </ul>								
Lung cancer incidence (The following field	apply if the procedure resulted in a tissue/cytology diagnosis. Not applicable for imag	ing follow-up.)							
5B4. Tissue/cytology diagnosis	O       Benign       O       Malignant - invasive lung cancer       O       Malignant - minimally invasive lung cancer         O       Malignant - adenocarcinoma in situ       O       Premalignancy - atypical adenomatous hyperplasia       O       Non-diagnostic         O       Malignant (not adenocarcinoma), lung cancer, invasive status unknown       O       Unknown       O       Clinical - without histology	<ul> <li>Malignant - Non- lung cancer</li> <li>Malignant - Carcinoid</li> <li>Malignant (not adenocarcinoma), lung cancer, non- invasive</li> </ul>							
	specify:								
5B5. Tissue/cytology diagnosis method	Select one: O Percutaneous (non- O Bronchoscopic surgical)	O Surgical O Unknown							
	Select one: O L hilum – Left O Lingula – Lingula of O LLL – Left lower hilum lung lobe of lung	O LUL – Left upper lobe of lung							
5B6. Location from which sample was obtained:	O R hilum – Right O RLL – Right lower O RML – Right hilum lobe of lung middle lobe of lung	O RML/RLL – Right middle and right lower lobes of lung							
	O RU/RM – Right upper and right middle lobes of O RUL – Right upper lol	be of lung							
	O Other, please	O Unknown							

# \* Required field

American College of Radiology

nrdr.acr.org

v 1.27

	Select one:									
	0 Non-small cell lung cancer. Select one:									
	O Invasive adenocarcinoma									
	O Squamous cell carcinoma									
	O Adenosquamous cell carcinoma									
	O Undifferentiated or poorly differentiated carcinoma									
5B7. Histology of primary or dominant	O Large cell carcinoma									
cell type	O Other, please specify:									
	O High grade neuroendocrine tumor (small cell lung cancer)									
	O Low grade neuroendocrine tumor (carcinoid)									
	O Intermediate grade neuroendocrine tumor (atypical carcinoid)									
	O Other, please specify:									
	O Unknown									
	Select one:									
	O Non-small cell lung cancer. Select one:									
	O Invasive adenocarcinoma									
	O Squamous cell carcinoma									
	O Adenosquamous cell carcinoma									
	O Undifferentiated or poorly differentiated carcinoma									
5B8. Histology of secondary cell type	O Large cell carcinoma									
	O Other, please specify:									
	O High grade neuroendocrine tumor (small cell lung cancer)									
	O Low grade neuroendocrine tumor (carcinoid)									
	O Intermediate grade neuroendocrine tumor (atypical carcinoid)									
	O Other, please specify:									
	O Unknown									
5B9. Stage – Clinical or pathologic?	O Clinical O Pathologic O Unknown									
	Select one:									
	0 0 0 IA 0 IA1 0 IA2									
5B10. Overall stage	O IA3 O IB O IIA O IIB									
	O IIIA O IIIB O IIIC O IV									
	O IVA O IVAB O Unknown									
	Select one:									
5B11. T Status	Отх Ото Отіа Отіь									
	O T1c O T1mi O T2a O T2b									
	O T3 O T4 O Tis O Unknown									
5B12. N Status	Select one: O NX O NO O N1 O N2 O N3									
5B13. M Status	Select one: O MX O M0 O M1a O M1b O M1c									
5B14. AJCC Cancer Staging Manual edition used for staging	Select one: O 7 <sup>th</sup> Edition O 8 <sup>th</sup> Edition O Other/Unknown									
5C. Additional risk factors										
Note: The fields in castion 50 and and	uired if "Examination Date" less "Patient's Date of Birth" is greater than 80 years of age or less than									
50 years of age OR										
"Number of packs-year smoking" is l	ess than 20 OR									
"Number of Years Quit" is more than	15									
5C1. Radon exposure – documented	O No O Yes O Not sure / Unknown									
high exposure levels:	O No O Yes O Not sure / Unknown									

# \* Required field

nrdr.acr.org

v 1.27

	Seleo	ct all that apply:							
		Silica		Cadmium		Asbestos	I		Arsenic
5C2. Occupational exposures to agents that are identified as carcinogens		Beryllium		Chromium		Diesel fumes	I		Nickel
targeting the lungs		Coal Smoke		Soot		Unknown	I		None
		Other, Please specify:	_						
	Seleo	ct all that apply:							
		lung cancer Other smoking related cancers, please specify:		Lymphoma		Head and neck			Bladder cancer
				Acute myeloid leukemia		cancer Colorectal cancer			Esophageal cancer
5C3. History of cancers that are				Liver cancer		colorectal cancer			Kidney cancer
associated with an increased risk of				Pancreatic cancer		Gastric cancer			Unknown whether
developing a new primary lung cancer						No history of cancers			patient has a history of cancers
									associated with an increased risk of
									new primary lung cancer
FC4 hund concernin first docurs									
5C4. Lung cancer in first-degree relative (mother, father, sister, brother, daughter or son with history of lung cancer):	0	No		O Yes		0	Not s	sure	e / Unknown
5C5. Family history of lung cancer, other than first-degree relative:		No		O Yes		0	Not s	sure	e / Unknown
5C6. COPD:		No		O Yes		0	Not s	sure	e / Unknown
5C7. Pulmonary fibrosis:		No		O Yes		0	Not s	sure	e / Unknown
5C8. Second hand smoke exposure:		No		O Yes		0	Not s	sure	e / Unknown
6. *Name of person who completed	Last	: name:							
the paper form:		t name:							